Clinical trials: Anaplastic Thyroid Cancer, open to volunteers
Thyroid Carcinoma, Anaplastic
Taiwanese Anaplastic Thyroid Cancer Registry
Primary treatment strategies for ATC have included surgical resection combined with radiotherapy, chemotherapy, or concurrent chemoradiation therapy.
- Trial name
- TATC (NCT07138261)
- Where
- 9 sites in Taiwan
- Volunteers
- 100 people
- Sponsor
- National Health Research Institutes, Taiwan
Anaplastic Thyroid Cancer, Thyroid Cancer
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
This multicenter study examines the safety and feasibility of the combination of neoadjuvant XL092 and cemiplimab prior to surgical resection in participants with wild-type (WT) anaplastic thyroid cancer (ATC) that has a BRAF…
- Conditions
- Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Mutation-Related Tumors
- Trial name
- NEO-COMBATXL (NCT06902376)
- Testing
- Cemiplimab, XL092
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Thyroid Cancer
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
The researchers are doing this study to find out if the combination of avutometinib and defactinib is an effective treatment for RAF dimer-driven radioiodine-refractory differentiated thyroid cancer or anaplastic thyroid cancer.
- Trial name
- NCT06007924
- Testing
- Avutometinib, Defactinib
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer
Sacituzumab govitEcan in THYroid Cancers
SETHY is a prospective, multicohort, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study of sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory differentiated…
- Trial name
- SETHY (NCT06235216)
- Testing
- Sacituzumab govitecan
- Where
- 11 sites in Spain
- Volunteers
- 42 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- 2 sites in United States, Australia
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Anaplastic Throid Carcinoma
Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC
The patients with anaplastic thyroid cancer were treated with CAR-NK immune cells combined with PD-1 monoclonal antibody, and the safety and tolerability of the patients were observed and evaluated.
- Trial name
- NCT06856278
- Testing
- NKG2D CAR-NK with PD-1 Antibody
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Provincial People's Hospital
Haematological Malignancy, Melanoma
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
This clinical trial is looking at a combination of drugs called vemurafenib and cobimetinib. Vemurafenib is approved as standard of care for adult patients with unresectable or metastatic melanoma.
- Conditions
- Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms
- Trial name
- DETERMINE (NCT05768178)
- Testing
- Vemurafenib, Cobimetinib
- Where
- 16 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Thyroid Gland Anaplastic Carcinoma, Poorly Differentiated Thyroid Carcinoma
[177Lu]Lu-AKIR001 First-in-human Study
The goal of this clinical trial is to evaluate the safety and tolerability of increasing doses of [177Lu]Lu-AKIR001, both in relation to tolerable activity of lutetium-177 and the absorbed protein mass dose of AKIR-001 in…
- Conditions
- Thyroid Gland Anaplastic Carcinoma, Poorly Differentiated Thyroid Carcinoma, Cancer Head and Neck, Cervix Carcinoma
- Trial name
- AKIR001 (NCT06639191)
- Testing
- [177Lu]Lu-AKIR001
- Where
- Sweden
- Volunteers
- 15 people
- Sponsor
- Karolinska University Hospital
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in…
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT07440290)
- Testing
- Dabrafenib, Trametinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Locally Advanced Thyroid Gland Carcinoma, Thyroid Cancer
Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer
The current study aims to explore the potential advantages of chemotherapy that is implemented based on drug sensitivity testing.
- Trial name
- NCT06713057
- Testing
- Cyclophosphamide+Pemetrexed+5-Fluorouracil, Cyclophosphamide+Doxorubicin+5-Fluorouracil, Vindesine + Cisplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- West China Hospital
Anaplastic Thyroid Cancer
NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)
Anaplastic thyroid cancer (ATC) is an almost invariable lethal cancer in humans. Most patients present with a rapid progressive mass in the neck with progressive complaints like dyspnoea, dysphagia or pain.
- Trial name
- NEO-ATACT (NCT06079333)
- Testing
- dabrafenib/trametinib
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Leiden University Medical Center
Cancer Harboring BRAF Alterations, HGG
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive…
- Conditions
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Trial name
- NCT05503797
- Testing
- Plixorafenib
- Where
- 70 sites in United States, Australia and 10 more
- Volunteers
- 254 people
- Sponsor
- Fore Biotherapeutics
Anaplastic Thyroid Cancer
Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer
This pilot phase 2 study evaluate the effectiveness and safety of pembrolizumab and lenvatinib in patients with anaplastic thyroid cancer.
- Trial name
- NCT06374602
- Testing
- Pembrolizumab + Lenvatinib
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- Saint Petersburg State University, Russia
Melanoma, Medullary Thyroid Cancer
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites.
- Conditions
- Melanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma, Esthesioneuroblastoma
- Trial name
- RABBIT (NCT06814496)
- Testing
- Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Arizona
Thyroid Cancer
Selective Coverage Versus Comprehensive Coverage Radiotherapy in Poorly Differentiated and Anaplastic Thyroid Cancer
To explore the efficacy and safety of selective coverage radiotherapy in poorly differentiated and anaplastic thyroid cancer
- Trial name
- NCT07777536
- Testing
- Selective coverage radiotherapy, comprehensive coverage radiotherapy
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Fudan University
Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic NUT Carcinoma
Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma
This trial tests how well giving enfortumab vedotin works for the treatment of differentiated thyroid cancer that does not respond to treatment with radioiodine (refractory), anaplastic thyroid cancer, medullary thyroid cancer or…
- Conditions
- Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic NUT Carcinoma, Metastatic Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Medullary Carcinoma
- Trial name
- NCT07863765
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Northwestern University
Advanced Thyroid Carcinoma, Radioiodine-refractory Differentiated Thyroid Cancer
Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer
This is a multicenter, open-label, multi-cohort Phase II exploratory study designed to evaluate the efficacy and safety of sacituzumab tirumotecan with or without tislelizumab in patients with unresectable, locally advanced, or…
- Conditions
- Advanced Thyroid Carcinoma, Radioiodine-refractory Differentiated Thyroid Cancer, Poorly Differentiated Thyroid Carcinoma
- Trial name
- NCT07068542
- Testing
- Sacituzumab Tirumotecan (SKB264) plus Tislelizumab, Sacituzumab Tirumotecan (SKB264)
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Zhejiang Provincial People's Hospital
Anaplastic Thyroid Cancer
Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer
The goal of the trial is to improve this OS by 4 months (to 9.9 months) using the zanzalintinib + cemiplimab treatment combination.
- Trial name
- NCT07470489
- Testing
- Cemiplimab, Zanzalintinib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Thyroid Cancer
GETNE Registration of Thyroid Cancer
An epidemiological, observational, multicenter, cross-sectional, retrospective study on patients ≥ 18 years visited in the oncology services of the participating centers with diagnosis of primary thyroid cancer.
- Trial name
- NCT03765333
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Anaplastic Thyroid Carcinoma, Thyroid Cancer
Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer
This study is a single institution non-randomized phase 2 trial looking at the effect of Pulsed Stereotactic Ablative Radiotherapy (PULSAR) followed by neoadjuvant chemotherapy dabrafenib and trametinib (DT) with or without…
- Conditions
- Anaplastic Thyroid Carcinoma, Thyroid Cancer, Thyroid Carcinoma
- Trial name
- NCT07886905
- Testing
- Dabrafenib, Trametinib, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Washington University School of Medicine